Sanofi and T1D Exchange launch global study on World Diabetes Day

Hannah Blake

pharmaphorum

To coincide with World Diabetes Day, Sanofi has announced its plans to collaborate with T1D Exchange on the TEENs registry study. T1D Exchange is a not-for-profit organisation that is focused on type 1 diabetes.

The TEENs registry study, also known as the “Glycemic control and quality of life in children, adolescents, and young adults with type 1 diabetes mellitus described in a worldwide, cross-sectional study in 2012,” aims to deliver recommendations for better disease management and patients outcomes. It also aims to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes.

The study will involve over 7,000 people with type 1 diabetes in 20 countries and will evaluate the percentage of type 1 diabetes patients between the ages of 8 and 25 with controlled glycemia, as measured by hemoglobin A1c (HbA1c). Sanofi and T1D Exchange will help with patient recruitment for the study in the United States.

“To better understand how to treat young people with type 1 diabetes, we need to know how exactly they are living with the disease. Our goal with the TEENs study is to examine how clinical factors such as glycemic control impact the quality of life of this particularly vulnerable group of young people with diabetes. TEENs is another example of Sanofi’s ongoing commitment to further develop the understanding of optimal type 1 diabetes care.”

Riccardo Perfetti, MD, Vice President Medical Affairs, Global Diabetes, Sanofi.

Results from the TEENs study will be presented at scientific congresses in 2013 and in 2014.

Collaborations, such as this, are particularly important in the area of diabetes, as there are over 18 million people worldwide living with type 1 diabetes. According to the International Diabetes Federation, diabetes is running at record levels worldwide – with approximately 371 million people worldwide living with either type 1 or type 2 diabetes – and half the people estimated to have the disease are, as yet, undiagnosed. This number is expected to reach 552 million by 2030.

Boehringer Ingelheim also aims to raise further awareness of this global diabetes epidemic and provided €20,000 in financial support for the International Diabetes Federation. Over 450 of the company’s employees participated in a 3km run on Tuesday 13th November in the knowledge that each kilometre completed would be convert into a monetary contribution to the IDF’s ‘Life for a Child’ programme.

&nbsp,